Further studies demonstrated that BET-targeted PRTOAC was able to inhibit cell proliferation of multiple human-derived MM cell lines and fresh myeloma samples and suggested potential synergy with systemic agents including selinexor [275]. Here, DNER is linked to Miyoshi myopathy.